Brokerages Set Smith & Nephew SNATS, Inc. (NYSE:SNN) Price Target at $30.93

Shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) have been assigned a consensus rating of “Hold” from the nine ratings firms that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, six have issued a hold rating and two have given a buy rating to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $30.9250.

Several research analysts have recently commented on SNN shares. Canaccord Genuity Group decreased their price target on shares of Smith & Nephew SNATS from $32.00 to $30.00 and set a “hold” rating for the company in a report on Monday, May 11th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Smith & Nephew SNATS in a research note on Thursday. Morgan Stanley reissued an “overweight” rating on shares of Smith & Nephew SNATS in a report on Wednesday. Kepler Capital Markets lowered Smith & Nephew SNATS from a “buy” rating to a “hold” rating in a report on Thursday, June 4th. Finally, The Goldman Sachs Group reiterated a “buy” rating on shares of Smith & Nephew SNATS in a research report on Monday, May 25th.

Smith & Nephew SNATS Stock Performance

SNN stock opened at $30.10 on Monday. The company has a current ratio of 2.14, a quick ratio of 1.11 and a debt-to-equity ratio of 0.62. Smith & Nephew SNATS has a 1-year low of $28.56 and a 1-year high of $38.79. The firm has a fifty day moving average price of $30.46 and a two-hundred day moving average price of $32.12.

Smith & Nephew SNATS Dividend Announcement

The business also recently disclosed a dividend, which will be paid on Friday, November 6th. Investors of record on Friday, October 2nd will be paid a dividend of $0.312 per share. This represents a yield of 205.0%. The ex-dividend date is Friday, October 2nd.

Institutional Investors Weigh In On Smith & Nephew SNATS

Hedge funds have recently added to or reduced their stakes in the stock. Perpetual Ltd bought a new position in shares of Smith & Nephew SNATS in the fourth quarter worth $1,518,000. Teachers Retirement System of The State of Kentucky increased its holdings in shares of Smith & Nephew SNATS by 31.8% during the fourth quarter. Teachers Retirement System of The State of Kentucky now owns 599,500 shares of the medical equipment provider’s stock valued at $19,670,000 after purchasing an additional 144,800 shares during the period. Deprince Race & Zollo Inc. raised its stake in shares of Smith & Nephew SNATS by 10.6% during the fourth quarter. Deprince Race & Zollo Inc. now owns 375,955 shares of the medical equipment provider’s stock valued at $12,335,000 after purchasing an additional 36,072 shares in the last quarter. Todd Asset Management LLC raised its stake in shares of Smith & Nephew SNATS by 30.2% during the fourth quarter. Todd Asset Management LLC now owns 944,578 shares of the medical equipment provider’s stock valued at $30,992,000 after purchasing an additional 219,348 shares in the last quarter. Finally, Quantinno Capital Management LP lifted its holdings in Smith & Nephew SNATS by 46.3% in the first quarter. Quantinno Capital Management LP now owns 278,224 shares of the medical equipment provider’s stock worth $8,842,000 after purchasing an additional 88,068 shares during the period. 25.64% of the stock is currently owned by institutional investors.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.